Philip Arlen, PhD

Chief Scientific Officer and Senior Vice President
Diverse Biotech, Inc.

Dr. Arlen directs scientific and R&D activities for Diverse Biotech, Inc., an early stage biotechnology company. The company is developing novel therapeutics based on cannabinoids using its proprietary conjugate synthesis platform. Combining cannabinoids with known therapeutic agents has the potential to lower doses of potent drugs, reduce toxicity and side effects, increase overall efficacy, and assist in patient recovery.

Dr. Arlen’s career began at the Prostate Cancer Foundation, where he helped Michael Milken create the first nationwide organization of translational research scientists and clinicians dedicated to eradicating prostate cancer. After completing his post-doctoral work in plant biotechnology to generate therapeutics and vaccines, Dr. Arlen joined the MD Anderson Cancer Center as a faculty memeber. He directed the Early Stage Interventions Laboratory, which studied the relationship between cancer and the immune system, with specific areas of focus in cancer vaccines, tumor biomarkers, and immunodiagnostics. Dr. Arlen left academia to lead scientific activities for Revolution Medicine, an MD Anderson spin-out that provides personalized medicine solutions. Immediately prior to joining Diverse Biotech, he was part of the drug discovery leadership team at Sanford Burnham Prebys Medical Discovery Institute.

Dr. Arlen earned a BS in Biology from Cornell University and PhD in Microbiology, Immunology, and Molecular Genetics from the University of California, Los Angeles.